Syros Pharmaceuticals, Inc. (SYRS)

Syros Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	6.98	9.94	14.88	23.49	15.09	1.98
Revenue Growth (YoY)	-43.55%	-33.23%	-36.65%	55.62%	661.50%	-3.32%
Gross Profit	6.98	9.94	14.88	23.49	15.09	1.98
Selling, General & Admin	27.14	28.28	29.3	23.04	21.33	21.48
Research & Development	104.05	108.15	111.94	99.87	76.07	58.25
Other Operating Expenses	2.49	2.49	9.51	0	0	0
Operating Expenses	133.68	138.92	150.75	122.91	97.39	79.72
Operating Income	-126.7	-128.99	-135.87	-99.42	-82.3	-77.74
Interest Expense / Income	5.22	5.13	4.13	3.91	1.79	0.07
Other Expense / Income	12.58	30.46	-45.35	-16.77	-0.05	-2.38
Pretax Income	-144.49	-164.57	-94.65	-86.56	-84.04	-75.44
Net Income	-144.49	-164.57	-94.65	-86.56	-84.04	-75.44
Shares Outstanding (Basic)	39	28	13	6	5	4
Shares Outstanding (Diluted)	39	28	13	6	5	4
Shares Change	40.00%	124.24%	102.00%	35.79%	14.49%	23.17%
EPS (Basic)	-5.05	-5.81	-7.49	-13.84	-18.20	-18.80
EPS (Diluted)	-5.05	-5.81	-7.49	-13.84	-18.20	-18.80
Free Cash Flow	-102.35	-108.42	-124.31	-100.79	-60.7	-72.78
Free Cash Flow Per Share	-2.63	-3.83	-9.84	-16.12	-13.18	-18.09
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-1814.88%	-1298.19%	-913.13%	-423.28%	-545.27%	-3922.35%
Profit Margin	-2069.80%	-1656.34%	-636.12%	-368.52%	-556.80%	-3806.16%
Free Cash Flow Margin	-1466.15%	-1091.17%	-835.39%	-429.09%	-402.17%	-3672.10%
EBITDA	-137.32	-157.12	-87.55	-79.63	-79.21	-72.64
EBITDA Margin	-1967.02%	-1581.31%	-588.39%	-339.04%	-524.82%	-3665.19%
Depreciation & Amortization	1.96	2.33	2.97	3.02	3.04	2.72
EBIT	-139.28	-159.45	-90.52	-82.65	-82.25	-75.37
EBIT Margin	-1995.07%	-1604.74%	-608.33%	-351.89%	-544.93%	-3802.52%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).